Telix completes enrollment for first-line glioblastoma study
Go back to Telix completes enrollment for first-line glioblastoma study| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 10.04 -0.05 (0.5%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.09 | 52 Week High | $2.18 | |||
| Open | $10.47 | 52 Week Low | $0.30 | |||
| Day High | $10.47 | P/E | N/A | |||
| Day Low | $10.02 | EPS | $-3.32 | |||
| Volume | 52,626 | |||||
